-
公开(公告)号:US20230129258A1
公开(公告)日:2023-04-27
申请号:US17630747
申请日:2020-07-30
申请人: BicycleTx Limited
IPC分类号: C07K14/705 , C07K7/08 , A61K47/64 , A61K9/00
摘要: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to two or more second peptide ligands, which bind to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
-
公开(公告)号:US20220242911A1
公开(公告)日:2022-08-04
申请号:US17592966
申请日:2022-02-04
申请人: BicycleTx Limited
摘要: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
-
公开(公告)号:US20230220008A1
公开(公告)日:2023-07-13
申请号:US18055255
申请日:2022-11-14
申请人: BicycleTx Limited
发明人: Liuhong CHEN , Rachid LANI , Kevin MCDONNELL , Gemma MUDD , Peter U. PARK , Punit UPADHYAYA
IPC分类号: C07K7/08 , C07K17/02 , A61K47/59 , C07K14/705 , A61K47/66 , A61K47/60 , C07K2/00 , A61K47/64 , C07K17/14 , C07K7/64 , A61P35/00 , A61K47/54
CPC分类号: C07K7/08 , C07K17/02 , A61K47/59 , C07K14/70575 , A61K47/66 , A61K47/60 , C07K2/00 , A61K47/64 , C07K17/14 , C07K7/64 , A61P35/00 , A61K47/54 , C07K2319/00
摘要: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
-
公开(公告)号:US20210040154A1
公开(公告)日:2021-02-11
申请号:US16941614
申请日:2020-07-29
申请人: BicycleTx Limited
摘要: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
-
公开(公告)号:US20220306689A9
公开(公告)日:2022-09-29
申请号:US17044868
申请日:2019-12-23
申请人: BicycleTx Limited
发明人: Liuhong CHEN , James COOKE , Kevin MCDONNELL , Gemma MUDD , Katerine VAN RIETSCHOTEN , Punit UPADHYAYA
摘要: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.
-
公开(公告)号:US20220088207A1
公开(公告)日:2022-03-24
申请号:US17416562
申请日:2019-12-23
申请人: BicycleTx Limited
发明人: Liuhong CHEN , James COOKE , Kevin MCDONNELL , Gemma MUDD , Katerine VAN RIETSCHOTEN , Punit UPADHYAYA
摘要: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.
-
公开(公告)号:US20210101933A1
公开(公告)日:2021-04-08
申请号:US17080021
申请日:2020-10-26
申请人: BicycleTx Limited
发明人: Liuhong CHEN , Rachid LANI , Kevin MCDONNELL , Gemma MUDD , Peter U. PARK , Punit UPADHYAYA
IPC分类号: C07K7/08 , A61K47/59 , A61K47/60 , A61K47/64 , A61K47/66 , A61P35/00 , C07K7/64 , C07K14/705 , C07K17/02 , C07K17/14 , C07K2/00
摘要: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
-
公开(公告)号:US20220275053A1
公开(公告)日:2022-09-01
申请号:US17630754
申请日:2020-08-13
申请人: BicycleTx Limited
IPC分类号: C07K14/705 , A61K47/64 , C07K7/06 , A61P35/00
摘要: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold, characterised in that said multimeric binding complex additionally comprises a modifier group conjugated thereto. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said multimeric binding complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said multimeric binding complexes and drug conjugates and to the use of said multimeric binding complexes and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137 and to the use in an analytical method (i.e. as a tracer or a tag).
-
公开(公告)号:US20220257784A1
公开(公告)日:2022-08-18
申请号:US17630314
申请日:2020-07-30
申请人: BicycleTx Limited
摘要: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also relates to pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).
-
公开(公告)号:US20220194983A1
公开(公告)日:2022-06-23
申请号:US17254339
申请日:2019-06-19
申请人: BicycleTx Limited
发明人: Daniel TEUFEL , Gemma MUDD , Silvia PAVAN , Kevin MCDONNELL , Punit UPADHYAYA
摘要: A peptide ligand specific for prostate specific membrane antigen (PSMA) comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.
-
-
-
-
-
-
-
-
-